Results 21 to 30 of about 451,745 (342)

Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Antimicrobial Agents and Chemotherapy, 2022
Islatravir (ISL) is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) that inhibits human immunodeficiency virus (HIV) reverse transcription by blocking reverse transcriptase (RT) translocation on the primer:template.
Tracy L. Diamond, Winnie Ngo, Min Xu, S. Goh, Silveria Rodriguez, M. Lai, E. Asante-Appiah, J. Grobler   +7 more
semanticscholar   +1 more source

Cost-effectiveness of the third-agent class in treatment-naive human immunodeficiency virus-infected patients in Portugal. [PDF]

PLoS ONE, 2012
IntroductionCurrent Portuguese HIV treatment guidelines recommend initiating antiretroviral therapy with a regimen composed of two Nucleoside Reverse Transcriptase Inhibitors plus one Non-nucleoside Reverse Transcriptase Inhibitor (2NRTI+NNRTI) or two ...
Filipa Aragão, José Vera, Inês Vaz Pinto   +2 more
doaj   +1 more source

Capacity of rTth polymerase to detect RNA in the presence of various inhibitors. [PDF]

PLoS ONE, 2018
The full potential of the real-time reverse transcription polymerase chain reaction (RT-PCR) as a rapid and accurate diagnostic method is limited by DNA polymerase inhibitors as well as reverse transcriptase inhibitors which are ubiquitous in clinical ...
Dongyang Cai, Ole Behrmann, Frank Hufert, Gregory Dame, Gerald Urban   +4 more
doaj   +1 more source

In silico prediction of telomerase reverse transcriptase inhibitors using modified retinol for the treatment of arsenical cancer

Bangabandhu Sheikh Mujib Medical University Journal, 2016
Retinol molecule was modified to predict the inhibitors of telomerase reverse transcriptase for the treatment of arsenical cancer through in silico study. Telomerase activity is expressed in the cancerous conditions which can be the target for anticancer
Kipchu Tshering, Mir Misbahuddin
doaj   +1 more source

Effect of reverse transcriptase inhibitors on LINE-1 and Ty1 reverse transcriptase activities and on LINE-1 retrotransposition [PDF]

, 2011
Background LINE-1s (L1, Long Interspersed Element-1) are the most abundant autonomous non-LTR retrotransposons in the human genome and replicate by reverse transcription of an RNA intermediate.
Lixin Dai, Qing Huang, Jef D Boeke
core   +1 more source

Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières [PDF]

, 2008
OBJECTIVES: To describe the use of second-line protease-inhibitor regimens in Médecins Sans Frontières HIV programmes, and determine switch rates, clinical outcomes, and factors associated with survival.
Alexandra Calmy, Boyd, Braitstein, Calmy, Calmy, Chaiwarith, Colebunders, Daniel O'Brien, Ferradini, Gallant, Galárraga, Ivers, Laurent, Ledergerber, Mar Pujades-Rodríguez, Mocroft, Nicastri, Orrell, Pierre Humblet, Renaud-Théry, Srasuebkul, Sungkanuparph, Vasan, Vekemans, Walmsley   +24 more
core   +2 more sources

Antiretroviral treatment can affect the release of NO and EDCF, but EDH in rat arteries [PDF]

, 2012
This journal suppl. entitled: EDHF 2012 - 10th Anniversary MeetingDespite improving clinical outcomes, highly active antiretroviral therapy (HAART) is an independent potential risk factor for cardiovascular diseases.
Lee, SS, Leung, SWS, Nejad, A, Vanhoutte, PM   +3 more
core   +1 more source

Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol. [PDF]

PLoS Pathogens, 2006
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) target HIV-1 reverse transcriptase (RT) by binding to a pocket in RT that is close to, but distinct, from the DNA polymerase active site and prevent the synthesis of viral cDNA.
Anna Figueiredo, Katie L Moore, Johnson Mak, Nicolas Sluis-Cremer, Marie-Pierre de Bethune, Gilda Tachedjian   +5 more
doaj   +1 more source

High-level resistance to non-nucleos(t)ide reverse transcriptase inhibitor based first-line antiretroviral therapy in Ghana; A 2017 study

Frontiers in Microbiology, 2022
Expanding access to effective antiretroviral therapy (ART) is a major tool for management of Human Immunodeficiency Virus (HIV) infection. However, rising levels of HIV drug-resistance have significantly hampered the anticipated success of ART in persons
Prince Kofi Parbie, Christopher Zaab-Yen Abana, Christopher Zaab-Yen Abana, Christopher Zaab-Yen Abana, Dennis Kushitor, Theodore Worlanyo Asigbee, Theodore Worlanyo Asigbee, Nana Afia Asante Ntim, Nana Afia Asante Ntim, Gifty Addo-Tetebo, Maclean Richard Darko Ansong, Sampson Badu Ofori, Taketoshi Mizutani, Lucky Ronald Runtuwene, Masako Nishizawa, Koichi Ishikawa, Hiroshi Kiyono, Hiroshi Kiyono, Hiroshi Kiyono, William Kwabena Ampofo, Tetsuro Matano, Tetsuro Matano, Tetsuro Matano, Evelyn Yayra Bonney, Tadashi Kikuchi   +24 more
doaj   +1 more source

Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years

Acta Pharmaceutica Sinica B, 2019
Human immunodeficiency virus (HIV) is the primary infectious agent of acquired immunodeficiency syndrome (AIDS), and non-nucleoside reverse transcriptase inhibitors (NNRTIs) are the cornerstone of HIV treatment.
Chunlin Zhuang, C. Pannecouque, E. De Clercq, Fener Chen   +3 more
semanticscholar   +1 more source